Study of Vancomycin Levels in Adults Receiving Continuous Veno-Venous Hemodiafiltration with the OXiris Membrane for Acute Kidney Injury

What this Trial Is About

Researchers are studying how the antibiotic vancomycin behaves in patients with acute kidney injury AKI who are receiving continuous veno-venous hemodiafiltration CVVHDF using an oXiris membrane. This membrane is designed to absorb inflammatory substances, and prior lab studies suggest it may reduce vancomycin levels by about 20 percent. However, there is limited data from living patients, so this study aims to measure vancomycin levels to better understand its pharmacokinetics during this treatment. Participants receive vancomycin doses ranging from 7.5 to 10 mg per kilogram of body weight every 12 hours while undergoing CRRT with the oXiris membrane. Blood samples are collected at multiple time points before and after vancomycin dosing, specifically at 0 before dose, 2, 3, 4, 5, 6, 8, and 12 hours. These samples help calculate the area under the curve AUC and other pharmacokinetic parameters to assess how the drug is processed in the body during this therapy. Throughout the study, participants are closely monitored with blood tests to measure vancomycin levels and other key pharmacokinetic markers such as maximum concentration, elimination rate, volume of distribution, and half-life. The study also tracks patient outcomes including mortality, kidney recovery, and any adverse effects related to vancomycin over a one-year period. The total participation duration and follow-up details are aligned with these evaluations to ensure comprehensive data collection.

Pharmacokinetics Vancomycin CVVHDF with OXiris Membrane